EMBC vs SYK: fair value comparison
Embecta Corp. and Stryker Corporation · Updated 2026-10-19
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, EMBC currently sits closer to the top of our ranking by discount to fair value. SYK carries the stronger quality grade.
| EMBC | SYK | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $6.27 | $277.33 |
| 12-month range | $2.90–$14.64 | $269.75–$387.46 |
| Rank by discount to fair value | #11 of 108 Healthcare | #12 of 108 Healthcare |
| Quality grade | B | A |
| Leverage | Low | Moderate |
| Margin trend | Contracting | Expanding |
| Revenue growth | Declining | Strong |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Downtrend | — |
| DCF cross-check | — | Overvalued |
| 52-week position | The lower-middle quarter | The bottom quarter |
Full single-stock breakdowns: EMBC fair value analysis · SYK fair value analysis